Q-omics provides the consensus-scored TRIM13 profile across patient tissues and cancer cell-line models. TRIM13 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRIM13 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, TRIM13 RNA expression shows 21,120 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where TRIM13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM13 survival associations across molecular data types. TRIM13 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM13 RNA expression–survival associations across cancer types. High TRIM13 expression shows unfavorable associations in UVM, HNSC and ACC, but favorable associations in KIRC, UCEC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRIM13 RNA expression.
This table summarizes TRIM13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM13 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in KIRC, LIHC and CHOL. The KICH box plot shows higher TRIM13 RNA expression in normal versus tumor tissue (log2 FC = −1.217, t-test p < 0.001).
This table shows molecular features associated with TRIM13 in patient tissues and cancer cell lines. In patient samples, TRIM13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
